Cytokinetics, Incorporated (FRA:KK3A)

Market Cap	8.27B +159.5%
Revenue (ttm)	91.77M +450.6%
Net Income	-719.52M
EPS	-5.93
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	60.10
Previous Close	63.28
Day's Range	60.10 - 60.10
52-Week Range	27.00 - 69.44
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 5, 2026

About Cytokinetics

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in h...

• Industry: Pharmaceutical Preparations
• Founded: 1997
• Employees: 673
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: KK3A

Financial Performance

In 2025, Cytokinetics's revenue was $88.04 million, an increase of 376.56% compared to the previous year's $18.47 million. Losses were -$784.96 million, 33.2% more than in 2024.

Financial numbers in USD